The DESTINY-Breast03 trial showed higher progression-free survival (PFS) and overall response rate (ORR) in HER2-positive breast cancer patients with BM who were treated with T-DXd compared with those treated with T-DM112,13. This evidence concerns the gene ERBB2 and breast carcinoma.